Cargando…
Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
OBJECTIVES: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419617/ https://www.ncbi.nlm.nih.gov/pubmed/30668729 http://dx.doi.org/10.1093/jac/dky510 |
_version_ | 1783403982001012736 |
---|---|
author | Ciccaglione, Antonio Francesco Di Giulio, Mara Di Lodovico, Silvia Di Campli, Emanuela Cellini, Luigina Marzio, Leonardo |
author_facet | Ciccaglione, Antonio Francesco Di Giulio, Mara Di Lodovico, Silvia Di Campli, Emanuela Cellini, Luigina Marzio, Leonardo |
author_sort | Ciccaglione, Antonio Francesco |
collection | PubMed |
description | OBJECTIVES: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as the first-line treatment for H. pylori infection. METHODS: The bovine lactoferrin antimicrobial/antivirulence effect was analysed in vitro by MIC/MBC determination and twitching motility against six clinical H. pylori strains and a reference strain. The synergism was evaluated using the chequerboard assay. The prospective therapeutic trial was carried out on two separate patient groups, one treated with esomeprazole/amoxicillin/levofloxacin and the other with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin. Treatment outcome was determined with the [(13)C]urea breath test. RESULTS: In vitro, bovine lactoferrin inhibited the growth of 50% of strains at 10 mg/mL and expressed 50% bactericidal effect at 40 mg/mL. The combination of levofloxacin and bovine lactoferrin displayed a synergistic effect for all strains, with the best MIC reduction of 16- and 32-fold for levofloxacin and bovine lactoferrin, respectively. Bovine lactoferrin at one-fourth MIC reduced microbial motility significantly for all strains studied. In the in vivo study, 6 of 24 patients recruited had treatment failure recorded with esomeprazole/amoxicillin/levofloxacin (75% success, 95% CI 57.68%–92.32%), and in the group with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin, 2 out of 53 patients recruited had failure recorded (96.07% success, 95% CI 90.62%–101.38%). CONCLUSIONS: Bovine lactoferrin can be considered a novel potentiator for restoring susceptibility in resistant H. pylori strains. Bovine lactoferrin added to a triple therapy in first-line treatment potentiates the therapeutic effect. |
format | Online Article Text |
id | pubmed-6419617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64196172019-03-20 Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study Ciccaglione, Antonio Francesco Di Giulio, Mara Di Lodovico, Silvia Di Campli, Emanuela Cellini, Luigina Marzio, Leonardo J Antimicrob Chemother Original Research OBJECTIVES: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as the first-line treatment for H. pylori infection. METHODS: The bovine lactoferrin antimicrobial/antivirulence effect was analysed in vitro by MIC/MBC determination and twitching motility against six clinical H. pylori strains and a reference strain. The synergism was evaluated using the chequerboard assay. The prospective therapeutic trial was carried out on two separate patient groups, one treated with esomeprazole/amoxicillin/levofloxacin and the other with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin. Treatment outcome was determined with the [(13)C]urea breath test. RESULTS: In vitro, bovine lactoferrin inhibited the growth of 50% of strains at 10 mg/mL and expressed 50% bactericidal effect at 40 mg/mL. The combination of levofloxacin and bovine lactoferrin displayed a synergistic effect for all strains, with the best MIC reduction of 16- and 32-fold for levofloxacin and bovine lactoferrin, respectively. Bovine lactoferrin at one-fourth MIC reduced microbial motility significantly for all strains studied. In the in vivo study, 6 of 24 patients recruited had treatment failure recorded with esomeprazole/amoxicillin/levofloxacin (75% success, 95% CI 57.68%–92.32%), and in the group with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin, 2 out of 53 patients recruited had failure recorded (96.07% success, 95% CI 90.62%–101.38%). CONCLUSIONS: Bovine lactoferrin can be considered a novel potentiator for restoring susceptibility in resistant H. pylori strains. Bovine lactoferrin added to a triple therapy in first-line treatment potentiates the therapeutic effect. Oxford University Press 2019-04 2019-01-21 /pmc/articles/PMC6419617/ /pubmed/30668729 http://dx.doi.org/10.1093/jac/dky510 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Research Ciccaglione, Antonio Francesco Di Giulio, Mara Di Lodovico, Silvia Di Campli, Emanuela Cellini, Luigina Marzio, Leonardo Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study |
title | Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study |
title_full | Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study |
title_fullStr | Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study |
title_full_unstemmed | Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study |
title_short | Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study |
title_sort | bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of helicobacter pylori infection: an in vitro and in vivo study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419617/ https://www.ncbi.nlm.nih.gov/pubmed/30668729 http://dx.doi.org/10.1093/jac/dky510 |
work_keys_str_mv | AT ciccaglioneantoniofrancesco bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy AT digiuliomara bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy AT dilodovicosilvia bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy AT dicampliemanuela bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy AT celliniluigina bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy AT marzioleonardo bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy |